The AI Drug Discovery Market in 2026

Market-sizing firms disagree sharply on how big this category actually is, which tells you something useful on its own: the definition of "AI in drug discovery" is still being fought over. Grand View Research put the global market at $2.35 billion in 2025, projecting growth to $13.77 billion by 2033 at a 24.8% CAGR from 2026. Precedence Research scopes the category more broadly and puts 2025 revenue at $6.93 billion, rising to $16.52 billion by 2034 at a slower 10.10% CAGR. If you're writing a plan for investors or a grant panel, cite the narrower Grand View figure for the core discovery-software category and note the wider Precedence number if your business touches adjacent services (data infrastructure, lab automation, clinical-trial AI).

Oncology is the single largest therapeutic-area segment, holding roughly a 24.3% revenue share, ahead of neurology, infectious disease, and rare disease programmes. That concentration matters for a business plan: a platform that leads with a named oncology use case will read as more credible to reviewers than one claiming to serve "all of pharma" on day one.

Growth is being driven less by novel algorithms and more by structural pressure inside pharma: average cost to bring one drug to market still runs into the billions when failed candidates are counted, and pharma R&D budgets are under pressure to show faster, cheaper hit rates. That's the commercial wedge your plan should describe explicitly — not "AI is transforming healthcare" but "this specific pharma workflow currently costs $X and takes Y months; here's the number we cut it to."

A second driver worth naming in your plan is data availability rather than model quality alone. Public structural datasets, patent filings, and clinical-trial registries have grown enough in the last three years that a small team can now train a useful target-scoring or lead-optimisation model without owning a proprietary wet-lab dataset from day one — something that was simply not true five years ago. That shift is the reason so many new entrants are software-first rather than lab-first, and it's also why pharma buyers are increasingly skeptical of platforms that can't show which datasets underpin their claims.

Reviewers reading a business plan in this category will also ask where the money in the value chain actually sits. Right now it sits disproportionately with platform vendors that have already signed multi-year pharma contracts (Schrödinger, Dotmatics, Cresset) rather than with newer entrants still proving hit-rate claims. A credible plan should acknowledge this directly: early-stage ventures typically need one or two paid pilots, not a signed multi-year contract, to validate the model before a Series A conversation is realistic.

It's also worth noting what a business plan in this category should not claim. None of the leading platforms — not Insilico Medicine's ISM001-055, not any Exscientia or Recursion programme — has yet taken an AI-originated molecule through full regulatory approval to market. Framing your venture's near-term milestones around "getting a drug approved" rather than "landing a validated pharma pilot" or "advancing a target to preclinical candidate" sets an expectation your plan almost certainly cannot meet on a normal seed-to-Series-A timeline, and experienced reviewers will notice the mismatch immediately.

Choosing a Business Model

Almost every AI drug discovery business plan collapses into one of three models. Naming which one you are — explicitly, in the executive summary — is one of the fastest ways to make a plan credible, because investors and grant reviewers have seen all three fail for different reasons and want to know which risks apply to you.

Reference points worth naming in your plan: Recursion Pharmaceuticals raised roughly $1.8 billion and pursued the hybrid route before acquiring Exscientia for $688 million in 2024 to consolidate an end-to-end platform. Insilico Medicine also runs hybrid, with its ISM001-055 molecule the furthest any AI-designed compound has progressed (Phase 2, idiopathic pulmonary fibrosis). BenevolentAI and Healx both lean toward the platform-plus-partnership model, with BenevolentAI embedded inside AstraZeneca's discovery engine and Healx (Cambridge, UK) advancing a rare-disease programme into FDA-cleared Phase 2 trials for NF1 off the back of a $47M Series C in 2024.

Most first-time founders should not default to the integrated-pipeline model. It has the biggest headline valuations but also the longest cash-negative runway and the highest failure rate; SaaS-first or hybrid plans are usually what a lender, angel, or Innovate UK panel can actually underwrite in year one.

There is also a fourth, less glamorous option worth naming for very early founders: a services-first model, where the venture sells computational consulting (target scoring, virtual screening runs, ADMET prediction reports) to smaller biotechs on a project basis before it has a productised platform at all. Margins are lower — often 15-25% once contractor time is billed — but it generates real revenue from month one, funds the platform build, and produces exactly the case-study evidence a pharma buyer will later ask for before signing a SaaS contract. Several of the companies now running platform-licensing businesses, including smaller entrants competing with Schrödinger and Dotmatics, started this way rather than raising a large seed round against an unproven model.

Whichever model you choose, the business plan should state explicitly how the model changes what a reviewer needs to underwrite: a SaaS plan needs proof of pharma willingness to pay before the model is fully validated; a pipeline plan needs proof the founding team can survive a binary clinical read-out; a services plan needs proof of billable utilisation. Conflating these asks in one generic "AI platform" narrative is the single most common reason funding conversations stall at the first meeting.

A simple decision framework for a first-time founder: if you already have two or more pharma contacts willing to trial your tool on a real project, the SaaS or services-first model is almost always the right starting point, because you can validate willingness-to-pay before committing to a large raise. If your founding team's edge is a specific, defensible dataset or wet-lab capability that competitors can't easily replicate, the integrated-pipeline or hybrid model becomes more defensible, because the moat is the data or biology rather than the interface. If neither applies yet — no named pharma contact and no unique dataset — the honest answer is that the venture isn't ready for any of the three models, and the plan should say so, naming the specific milestone (a signed pilot, a licensed dataset, a validated benchmark) that would change that.

Startup Costs & Funding Routes

Launching a lean AI drug discovery venture — a small team, a cloud-based platform, one focused discovery programme — typically requires $175,000 to $1.5 million (£140,000–£1.2 million) in year one, well above what a typical local-service business plan template assumes. The spread is wide because compute and data costs scale with how ambitious your first discovery campaign is.

Cost Breakdown

• Cloud GPU compute for a discovery campaign (50K–200K H100 GPU-hours): $125,000–$640,000 (£100K–£505K)
• Chemical/biological database licensing (e.g. Enamine REAL Space, PubChem-enriched sets): $50,000–$400,000/yr (£40K–£315K/yr)
• Bespoke data curation (structure cleanup, activity-data standardisation): $200,000–$1,500,000 per project (£160K–£1.19M)
• Founding computational team (2–4 ML/computational-chemistry hires, first year): $280,000–$720,000 (£190K–£480K)
• Pilot-to-production platform build (assessment through first deployment): $175,000–$825,000 (£140K–£650K)
• Legal, IP, and regulatory advisory (foundation-model licensing terms, data-use agreements): $15,000–$60,000 (£12K–£48K)

Two numbers in that list deserve special attention when you're building the financial model. First, database licensing and data curation are recurring costs, not one-off setup costs — a venture that licenses Enamine REAL Space or an equivalent enriched chemical dataset should budget for renewal every year, and most founders underweight this in their year-one forecast because it feels like a "startup cost" rather than an ongoing cost of goods sold. Second, compute cost is usage-linked rather than fixed: a venture running three discovery campaigns in year one should budget three times the per-campaign compute figure, not assume the $125,000 lower bound applies to the whole year. Reviewers who have seen AI biotech financial models before will look specifically for whether compute is modelled as a variable cost that scales with pipeline activity.

A simple runway calculation illustrates why this matters. A team that raises $1.4 million and budgets $720,000 for the founding computational team, $325,000 for one discovery campaign's compute, $150,000 for data licensing and curation, and $60,000 for legal/regulatory advisory has committed $1.255 million of the raise before accounting for office costs, cloud infrastructure outside the campaign itself, or a second campaign — leaving roughly $145,000 of buffer. Modelling that buffer explicitly, rather than assuming "the rest covers overheads," is one of the clearest signals in a plan that the founder has actually built the cost model bottom-up rather than backed into a round number that sounds fundable.

Funding Routes

In the US, NIH SBIR and STTR grants are the most common non-dilutive route — Phase I awards run up to $323,090 and Phase II up to $2,153,927, with AI applied to drug discovery listed as an explicit NIH priority area. The programme was reauthorised for a further five years in April 2026, with standard application deadlines of September 5, January 5, and April 5. Venture capital remains the dominant route for anything beyond a Phase I-scale build: AI-driven biotech startups raised over $4.5 billion globally in a single recent year, led by Recursion, XtalPi, and Insilico Medicine.

In the UK, Innovate UK Smart Grants fund R&D projects up to £500,000, and a dedicated Frontier AI Discovery competition has offered UK SMEs shares of up to £3 million for feasibility studies with a credible scale-up route. The Seed Enterprise Investment Scheme (SEIS) lets a UK-registered founder raise up to £250,000 with 50% income tax relief for investors — the single most useful instrument for getting a first angel cheque into a pre-revenue computational biology venture. Similar early-stage instruments exist in the EU via national deep-tech grant schemes and in Switzerland through Innosuisse, which co-funds applied-research partnerships between startups and universities.

A practical sequencing point most first-time founders miss: grant funding and equity funding solve different problems and should not be blended casually in a plan's cash-flow table. SBIR Phase I and Innovate UK Smart Grants are non-dilutive but slow — a typical review-to-award cycle runs four to nine months — so they're best modelled as covering a specific, named technical milestone (the first discovery campaign, a validation study) rather than general operating costs. Equity or SEIS capital should cover the gap while the grant application is under review, not the other way around. Plans that show this sequencing explicitly, with dates rather than vague quarters, read as materially more fundable than plans that simply list every funding source in one undifferentiated pool.

Where to Build: Ecosystem Hubs

Location shapes hiring, partnership access, and grant eligibility more in this niche than in most business-plan categories, because computational biology talent and pharma partners are genuinely clustered in a handful of places.

Your plan doesn't need to promise a physical office in all four places on day one — most early teams stay remote-first and simply travel for partnership meetings — but naming which hub you are closest to, and why, signals to reviewers that you understand where your buyers and hires actually are.

Beyond the four anchor hubs above, a growing secondary tier is worth tracking in a competitor or market-context section: Toronto and Montreal (strong public ML research funding plus a lower cost base than the Bay Area), Singapore (a deliberate government push to attract AI-biotech relocations with co-investment funding), and San Diego (a deep bench of genomics and computational-chemistry talent alongside the Bay Area cluster). None of these currently rival Kendall Square or the Bay Area for pharma-partnership density, but they matter for a cost-of-hiring comparison: as a rough planning estimate (not a cited figure — verify current local salary data before using it in a real forecast), a comparable ML engineer role can cost noticeably less to hire in Toronto or Montreal than in the Bay Area, which can materially change a startup-cost table if your team is remote-first.

How These Ventures Make Money

SaaS platform licensing is the most predictable revenue line: annual contract values typically range from $500,000 to $15 million per pharma client depending on breadth of tool access, and this model held roughly 38.4% of total market revenue in 2025. Partnership and licensing deals pay less often but far more per event — upfront payments of $20 million to $100 million are common, with milestone and royalty structures that can aggregate past $1 billion across a multi-programme agreement, though that cash arrives over years, not up front.

A worked example: a platform-licensing venture with three pharma clients at an average $1.2 million annual contract value generates $3.6 million in ARR. Net margins on pure-software licensing revenue are an Avvale estimate — not a single cited external figure — built from the compute, data-licensing, and headcount cost ranges above; they typically land in the 21–53% range once cloud compute, data licensing renewals, and a small computational team are accounted for. That range sits wider than a services business and narrower than a pure SaaS company, because the compute cost scales with usage rather than staying fixed. Landing a single discovery-partnership deal with a $25 million upfront payment can double reported revenue in the year it closes, but that income is typically recognised over the life of the partnership rather than in one lump sum, which is a distinction reviewers of your financial model will check closely.

Companies pursuing the hybrid model generally use SaaS or fee-for-service revenue to self-fund one or two internal pipeline programmes rather than raising dilutive capital for them — this is the pattern behind Recursion's approach before its Exscientia acquisition, and it's the most defensible model for a first-time founder to underwrite in a business plan, because it doesn't require a binary trial outcome to keep the lights on.

A second worked example (illustrative planning scenario, not a cited industry figure), this time for the services-first path: a two-person founding team billing computational consulting work (virtual screening runs, ADMET prediction reports) at $8,000-$15,000 per project to smaller biotechs could realistically close 12-18 projects in a first year, generating roughly $110,000-$220,000 in revenue at a 40-55% gross margin once contractor and compute costs are deducted. That's not venture-scale revenue, but it's enough to self-fund an 18-24 month platform build without diluting the founders, and it's the pattern several smaller platform vendors used before they had a signed enterprise contract to point to.

Whatever model you choose, your financial model should separate three revenue lines clearly rather than blending them: recurring platform/SaaS revenue, one-off services revenue, and partnership upfronts plus milestones. Investors and grant panels specifically look for whether a founder understands that these three lines have entirely different cash-timing, margin, and renewal characteristics — collapsing them into a single "revenue" line is one of the fastest ways to lose credibility in a diligence conversation.

Regulatory & Licensing Requirements

United States

The FDA released its first draft guidance on AI in drug and biological product regulatory decision-making in January 2025. Critically, the guidance explicitly excludes AI systems used purely for internal drug discovery or operational improvements from its scope — the highest scrutiny applies only once an AI system's output is used to generate evidence for a regulatory submission (efficacy claims, trial design, safety data). By fall 2024 the FDA had already received over 500 submissions incorporating AI components across various development stages, and the agency's proposed "credibility framework" requires validation and documentation proportional to the AI's risk and role in the decision at hand.

• Standard corporate/biotech entity registration (Delaware C-corp is the default for VC-backed ventures)
• No FDA pre-clearance needed for internal discovery-only AI use
• Formal AI credibility assessment triggered only when AI output feeds a regulatory submission
• Data-use and IP agreements for any third-party chemical/biological databases
• HIPAA-compliant handling if any patient-level data is used in training sets

For a business plan, the practical takeaway is to describe the FDA relationship in two tiers. Tier one is your day-to-day discovery workflow — the target scoring, virtual screening, and lead optimisation your platform runs internally. This tier currently sits outside FDA guidance scope entirely, and a plan that overstates regulatory burden here will actually undermine credibility with pharma buyers who know the rules. Tier two is anything your platform's output directly supports in a client's regulatory submission — here, documentation, validation evidence, and a clear description of your model's intended use and limitations become necessary, and your plan should show you know the difference between the two tiers rather than treating "FDA regulation" as one undifferentiated compliance line.

United Kingdom

The MHRA is building a dedicated AI-specific regulatory framework for software and AI as a medical device, expected to publish in 2026, alongside its AI Airlock regulatory sandbox where companies test AI-driven approaches with direct MHRA supervision. A new international reliance pathway — letting a manufacturer with valid FDA, Health Canada, or Australian TGA authorisation use that as the basis for a streamlined UK application — is expected to open in the first half of 2026, which matters if you plan a US-first regulatory strategy before entering the UK.

European Union & International

The European Medicines Agency (EMA) finalised its reflection paper on the use of AI across the medicinal product lifecycle on 9 September 2024, covering everything from early discovery through post-authorisation monitoring. It mandates a human-centric, risk-based approach and due respect for existing legal and ethical requirements. The EMA and FDA have jointly published ten shared principles for good AI practice across the medicines lifecycle — the clearest signal yet that transatlantic regulators intend to converge on a single AI-governance standard rather than diverge.

One practical consequence for founders raising in 2026: because the FDA, MHRA, and EMA are all converging around risk-based, documentation-heavy AI governance rather than blanket approval requirements, the compliance workload scales with how directly your output touches a regulatory submission, not with how much AI your platform uses. A plan that describes a proportionate, staged compliance roadmap — light-touch now, heavier once a pharma partner's submission depends on your output — will typically read as more sophisticated to a reviewer than one that either ignores regulation entirely or treats it as a single, large upfront cost.

Common Mistakes to Avoid

• Underestimating compute and data spend. Founders who budget for a discovery campaign as a "software cost" rather than the $125K-$640K in GPU-hours it actually consumes routinely run out of runway before a single campaign finishes.
• No wet-lab validation partner. A plan that positions the venture as a pure software company, with no lab that can validate hit-rate claims experimentally, reads as unfalsifiable to pharma buyers and investors alike.
• Ignoring the regulatory framework until a partner asks. FDA credibility-framework documentation and MHRA/EMA expectations take months to build; leaving this until diligence starts on a partnership is a common, avoidable delay.
• Building a generalist platform with no named pharma pipeline. Plans that claim to serve "all of pharma" with no named target, therapeutic area, or letter of intent have no proof of commercial pull for a reviewer to evaluate.
• Undefined foundation-model and training-data IP terms. Ambiguity over who owns outputs derived from third-party foundation models (or licensed datasets) is one of the most common reasons a partnership or fundraise stalls in due diligence.

Two subtler mistakes are worth calling out separately because they don't show up until a reviewer starts asking follow-up questions. The first is quoting a single hit-rate or accuracy number without stating the benchmark it was measured against — reviewers who have seen multiple AI drug discovery pitches will assume an unqualified "90% accuracy" claim is meaningless until you name the dataset and comparison method. The second is treating partnership revenue as guaranteed once a term sheet or letter of intent is signed; pharma partnerships routinely include go/no-go gates tied to preclinical data, and a plan that models 100% of a milestone schedule as certain, rather than probability-weighted, will read as naive to anyone who has actually negotiated one of these deals.

Sample Business Plan Preview

Here's an extract from a business plan structured on this exact template — so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors or grant reviewers in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and the specific regulatory requirements for AI-enabled drug development
• Target Market & Customer Analysis — Which pharma segment you sell to, and why they buy
• Competitor Analysis — Business-model-aware competitive mapping and your differentiation strategy
• Go-to-Market Plan — Partnership strategy, channels, and messaging for a pharma buyer
• Operations Plan — Compute, data, and team workflows, plus key technical milestones
• Management Team — Founder bios, scientific advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements — formatted so it can be adapted for an SBIR Phase I/II submission or an Innovate UK Smart Grant application.

For this specific niche, the forecast model separates compute cost as a variable line item tied to discovery-campaign volume rather than a fixed monthly cost, which is the single biggest difference between a generic SaaS financial model and one built for an AI drug discovery venture. It also includes a milestone/royalty schedule template for founders pursuing a partnership-heavy or hybrid model, so that potential upfront payments, milestones, and eventual royalty streams can be laid out on a timeline rather than lumped into one "other income" line — which is usually the first thing an experienced pharma business-development reviewer will ask you to fix.

Frequently Asked Questions

These are the questions we see most often from founders and researchers writing an AI drug discovery business plan for the first time — pulled from live search results and from calls with clients building in this exact niche.